Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses

Comparing Novartis and Halozyme's cost strategies over a decade.

__timestampHalozyme Therapeutics, Inc.Novartis AG
Wednesday, January 1, 20142273200017345000000
Thursday, January 1, 20152924500017404000000
Friday, January 1, 20163320600017520000000
Sunday, January 1, 20173115200017175000000
Monday, January 1, 20181013600018407000000
Tuesday, January 1, 20194554600014425000000
Wednesday, January 1, 20204336700015121000000
Friday, January 1, 20218141300015867000000
Saturday, January 1, 202213930400015486000000
Sunday, January 1, 202319236100012472000000
Monday, January 1, 202415941700012827000000
Loading chart...

In pursuit of knowledge

Cost Insights: Novartis AG vs. Halozyme Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. This analysis delves into the cost of revenue for Novartis AG and Halozyme Therapeutics, Inc. from 2014 to 2023. Over this period, Novartis AG consistently maintained a high cost of revenue, peaking in 2018 with a 15% increase from 2014. However, a notable decline of 28% was observed by 2023, reflecting strategic shifts or market dynamics. In contrast, Halozyme Therapeutics, Inc. exhibited a remarkable growth trajectory, with its cost of revenue surging by over 740% from 2014 to 2023. This stark contrast highlights the differing operational scales and market strategies of these two companies. As Novartis navigates its mature market position, Halozyme's rapid expansion underscores its aggressive growth strategy in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025